Andres Maldonado

Kelly Shi

Louise Chen

Joe Catanzaro

Albert Lowe

Bing Zhao

Gil Blum

Joseph Catanzaro

Qu Xiaoyi

Yingqi Peng

Zhuxuan Jiang

- I-Mab reported a **net loss of $8.654 million** for the six months ended June 30, 2025, compared to a net income of $9.106 million for the same period in 2024, with research and development expenses decreasing by **63.9%** to **$4.1 million**.  **[1778016_0001193125-25-230890_imab-20250630.htm:7]** **[1778016_0001193125-25-230890_imab-20250630.htm:14]** 
- The company completed an underwritten offering on **August 5, 2025**, raising approximately **$61.2 million** in net proceeds from the issuance of **33,333,330 American depositary shares (ADSs)** at **$1.95 per ADS**.  **[1778016_0001193125-25-230890_imab-20250630.htm:3]** **[1778016_0001193125-25-230890_imab-20250630.htm:37]** 
- As of June 30, 2025, cash and cash equivalents increased significantly to **$165.404 million**, up from $68.263 million as of December 31, 2024.  **[1778016_0001193125-25-230890_imab-20250630.htm:13]** 
- I-Mab expects to acquire **Bridge Health Biotech Co., Ltd** early in the fourth quarter of 2025 for an upfront payment of **$1.8 million** and potential milestone payments, gaining rights to bispecific and multi-specific applications based on the Claudin 18.2 parental antibody.  **[1778016_0001193125-25-230890_imab-20250630.htm:37]** 
- The divestiture of its Greater China assets and business operations was completed on **April 2, 2024**, for an aggregate consideration of up to **$80 million** contingent on future milestones and royalties.  **[1778016_0001193125-25-230890_imab-20250630.htm:3]** **[1778016_0001193125-25-230890_imab-20250630.htm:17]**

I-Mab Reports First Half 2025 Results, Underwritten Offering, and Strategic Acquisition

I-Mab (IMAB)